Bioretec updates estimate of U.S. registration of RemeOs™ screws and expects approval in April 2023
Bioretec Ltd Inside information 14 October 2022 at 5:45 p.m. EESTBioretec Ltd, a pioneer in bioresorbable orthopedic implants, continues to discuss the company's RemeOs™ trauma screw market authorization with the U.S. Food and Drug Administration (FDA). Based on the current information, Bioretec estimates to receive the authorization in April 2023. Previously the authorization was expected to be received in the second half of 2022. The company shall supplement the authorization request in accordance with the De Novo registration process by the end of 2022, after which the